Tibolone and its metabolits: a pharmacology, tissue's specifics and effects on experimental models of tumoures

Abstract

Tibolone represents steroid with wear estrogenic, progestagenic and androgenic properties, which can use as alternative usual hormonal replacement therapy (HRT). A series experiments for study influence of tibolone and its metabolits on a tissues in vitro and in vivo was conducted. The tissues selectivity of tibolone was found in a bone, where the estrogenic activity restores of a bones weight and quality the rats bone after ovarioectomy and the absence of estrogenic activity prevents of endometrial proliferation. Tibolone did note stimulate the cellular proliferation in the lines of tumoures crates and reduced a load of a tumour at the tumoures of mammary glands, called DMBA as on a model of preventive maintenance. It was shown that tibolone and each of from three metabolits considerably reduce in average load of the tumour after 10 weeks of treatment. These results show, that metabolits can introduce contribution to final effect of tibolone in the experiments in vivo and that metabolism plays a key role in a problem selective tissues effects of tibolone.

Keywords

tibolone / metabolites / pharmacology / tissue specificity / postmenopause / tumor models

References

[1] Tax L., Goorissen Е.М. and Kicovic P. M. Clinical profile of Org OD14. Maturitas, 1987, Suppl. 13-13.

[2] CittadiniJ., Ben J. and Badano A.R. The use of a new steroid (Org OD14) in the climacteric syndrome.

[3] Reproduccion, 1982. - №6. - P. 69- 79.

[4] Kicovic P.M., Cortes-Prieto J and Luisi M. Placebo-controlled crossover study of effects of Org OD 14 in menopausal women. Reproduccion, 1982. - № 6. -P. 81-91.

[5] Franchimont P., Franchi F. and Luidi M. Ovulation-inhibiting properties of Org OD14. Reproduccion, 1982. - №6. - P. 61-67.

[6] lindsay R., Hart D.M. and Kraszewski A. Prospective doublebind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br. Med. J., 1978. - №280. - P. 1207-1209.

[7] Bjarnson N. H., Bjarnson K., Hassager C. and Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone, 1997. - №20. -P. 151 -155.

[8] Nevinny-Stickel J. Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients. Arch. Gynecol., 1983. - №234. - P. 27- 31.

[9] Travoux R., Dieuland P. and Blum A. Efficacy and safety of Org OD 14 in the treatment of climacteric complaints. Maturitas, 1983. - №5. - P. 89-96.

[10] Genazzani A.R., Petraglia F. and Facchinetti F. Effects of Org OD 14 on pituitary and peripheral beta- endorphin in castrated rats and postmenopausal women. Presented at the 4 yj International Congress of the Menopause, Orlando, USA. Maturitas, 1984, Suppl., 35-48.

[11] Benedek-Jaszmann L.J. Longterm placebo-controlled efficacy and safety study of OrgOD 14 in climacteric women. Maturitas, 1987, Suppl., 25-33.

[12] Markiewicz L. and Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroid drug (OrgOD 14) and its metabolites on human endometrium. J. Steroid. Biochem., 1990. - №35. - P.535-541.

[13] Kloosterboer H.J., Schoonen W. G., Deckers G. H. and Klijn J. G. Effects of progestagens and OrgOD 14. I in vitro tumour models. J. Steroid. Biochem. Mol. Biol., 1994. - №49. -P. 311-318.

[14] Tang B., Markiewicz L., Kloosterboer H.J. and Gurpide T. Human sendometrial 3 bera-Hydrozysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic actMty ratios of a steroidal drug (OrgOD 14). J. Steroid. Biochem. Mol. Biol., 1993. - №45. - P. 345-351.

RIGHTS & PERMISSIONS

Eсо-Vector